Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
Study Details
Study Description
Brief Summary
studying the prevalence of hepatic steatosis and fibrosis in a large scale of patients with RA and healthy controls
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Rheumatoid arthritis patients
|
Diagnostic Test: ultrasonography
studying degree of steatosis
|
control
|
Diagnostic Test: ultrasonography
studying degree of steatosis
|
Outcome Measures
Primary Outcome Measures
- degree of hepatic steatosis [1 day during examination]
degree of hepatic steatosis by ultrasonography and Hepatic Steatosis Index.
- degree of hepatic fibrosis [1 day during examination]
degree of hepatic fibrosis by FIB-4 and APRI tests
Eligibility Criteria
Criteria
Inclusion Criteria:
-
RA according to the American College of Rheumatology (ACR)/EULAR 2010 criteria (Aletaha et al., 2010)
-
Age≥18 years
Exclusion Criteria:
-
History of hepatitis B and C virus infection.
-
Receiving hepatotoxic drugs other than RA-specific drugs.
-
Alcohol abuse (i30 g/day in men and ⩾20 g/day in women).
-
Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis.
-
Autoimmune liver disease.
-
Cancer.
-
Pregnancy.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sohag University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Soh-Med-22-11-17